Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
Portfolio Pulse from Vandana Singh
Johnson & Johnson announced long-term data from the Phase 1/2 MajesTEC-1 study of Tecvayli, showing sustained deep and durable responses in patients with relapsed or refractory multiple myeloma. The study demonstrated a 63% overall response rate and a 46% complete response rate. Safety profiles remained consistent, and the use of tocilizumab reduced the incidence of cytokine release syndrome.

June 03, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Tecvayli shows promising long-term results in multiple myeloma patients, with a 63% overall response rate and reduced severe infections.
The positive long-term data from the MajesTEC-1 study of Tecvayli, including high response rates and a consistent safety profile, is likely to boost investor confidence in Johnson & Johnson's oncology portfolio. The reduction in severe infections and the potential for outpatient administration further enhance the drug's appeal.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100